Showing 461 - 480 results of 27,277 for search '(( 50 ((ms decrease) OR (a decrease)) ) OR ( 50 ((we decrease) OR (nn decrease)) ))', query time: 0.92s Refine Results
  1. 461

    6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

    Published 2025
    “…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”
  2. 462

    6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

    Published 2025
    “…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”
  3. 463
  4. 464
  5. 465

    Supplementary Material for: Inverse and Direct Cancer Comorbidity in People with Central Nervous System Disorders: A Meta-Analysis of Cancer Incidence in 577,013 Participants of 50... by Catalá-López F. (4142920)

    Published 2014
    “…<b><i>Method:</i></b> Comprehensive search in PubMed/MEDLINE, Scopus and ISI Web of Knowledge of the literature published before March 2013. We identified 51 relevant articles from 2,229 discrete references, 50 of which contained data suitable for quantitative synthesis (577,013 participants). …”
  6. 466

    Dimerization of [Fe<sup>III</sup>(bpy)<sub>3</sub>]<sup>3+</sup> in Aqueous Solutions: Elucidating a Mechanism Based on Historical Proposals, Electrochemical Data, and Computationa... by Nicolas E. Holubowitch (9254254)

    Published 2022
    “…Despite these favorable characteristics, its oxidized Fe­(III) form undergoes dimerization to form μ-O-[Fe<sup>III</sup>(bpy)<sub>2</sub>(H<sub>2</sub>O)]<sub>2</sub><sup>4+</sup>, leading to a dramatic ∼0.7 V decrease during battery discharge. …”
  7. 467
  8. 468
  9. 469

    Circadian Genes, <i>xBmal1</i> and <i>xNocturnin</i>, Modulate the Timing and Differentiation of Somites in <i>Xenopus laevis</i> by Kristen L. Curran (95520)

    Published 2014
    “…We observed opposing effects on somite size. Depletion of xBMAL1 or xNOCTURNIN caused a statistically significant decrease in somite area (quantified using NIH ImageJ; p<0.002), while overexpression of these proteins caused a significant dose dependent increase in somite area (p<0.02; p<0.001, respectively). …”
  10. 470
  11. 471
  12. 472
  13. 473

    Transient VEP loss due to manipulation of the optic nerve. by Yeda Luo (710942)

    Published 2015
    “…At 15:00, the VEP decrease reached the warning criterion (50%) and a warning was issued to the surgeon who consequently altered the surgical strategy. …”
  14. 474
  15. 475
  16. 476

    Long-Term Effects of Botulinum Toxin Complex Type A Injection on Mechano- and Metabo-Sensitive Afferent Fibers Originating from <i>Gastrocnemius</i> Muscle by Guillaume Caron (816032)

    Published 2015
    “…After toxin injection, we observed a complete paralysis associated to a loss of force to muscle stimulation and a significant muscle atrophy, and a return to baseline when the animals recover. …”
  17. 477
  18. 478
  19. 479

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  20. 480

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”